메뉴 건너뛰기




Volumn 125, Issue 20, 2005, Pages

Neuraminidase inhibitors and their potential use in the avian influenza pandemic;Inhibidores de la neuraminidasa y su potencial utilización en la pandemia de gripe aviar

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

EID: 29944447234     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(05)72189-8     Document Type: Review
Times cited : (6)

References (44)
  • 2
    • 0037402154 scopus 로고    scopus 로고
    • The epidemiology and clinical impact of pandemic influenza
    • Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine. 2003;1762-8.
    • (2003) Vaccine , pp. 1762-1768
    • Nguyen-Van-Tam, J.S.1    Hampson, A.W.2
  • 5
    • 25444432780 scopus 로고    scopus 로고
    • The Writing Committee of the World Health Organization (WHO) consultation on human influenza A/H5. N Engl J Med. 2005;353:1374-85.
    • (2005) N Engl J Med , vol.353 , pp. 1374-1385
  • 7
    • 29944444522 scopus 로고    scopus 로고
    • Plan nacional de preparación y respuesta ante una pandemia de gripe
    • Mayo de
    • Plan nacional de preparación y respuesta ante una pandemia de gripe. Ministerio de Sanidad y Consumo. Mayo de 2005.
    • (2005) Ministerio de Sanidad Y Consumo
  • 8
    • 0344395604 scopus 로고    scopus 로고
    • Are we ready for pandemic influenza?
    • Webby RJ, Webster RG. Are we ready for pandemic influenza? Science. 2003;302:1519-22.
    • (2003) Science , vol.302 , pp. 1519-1522
    • Webby, R.J.1    Webster, R.G.2
  • 9
    • 0038037687 scopus 로고    scopus 로고
    • Pandemic influenza and the global vaccine supply
    • Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis. 2003;46:1552-61.
    • (2003) Clin Infect Dis , vol.46 , pp. 1552-1561
    • Fedson, D.S.1
  • 10
    • 11144356405 scopus 로고    scopus 로고
    • Responsiveness to a pandemic alert: Use of reverse genetics for rapid development of influenza vaccines
    • Webby RJ, Pérez DR, Coleman JS. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet. 2004;363:1099-103.
    • (2004) Lancet , vol.363 , pp. 1099-1103
    • Webby, R.J.1    Pérez, D.R.2    Coleman, J.S.3
  • 11
    • 0032934765 scopus 로고    scopus 로고
    • Profilaxis y tratamiento de las infecciones respiratorias causadas por los virus Influenza a y B
    • Reina J. Profilaxis y tratamiento de las infecciones respiratorias causadas por los virus Influenza A y B. Rev Esp Quimioterap. 1999;12:23-9.
    • (1999) Rev Esp Quimioterap , vol.12 , pp. 23-29
    • Reina, J.1
  • 12
    • 3142579867 scopus 로고    scopus 로고
    • Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia
    • Li KS, Guan Y, Wang J, Smith GJD, Xu KM, Duan L, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature. 2004;430:209-13.
    • (2004) Nature , vol.430 , pp. 209-213
    • Li, K.S.1    Guan, Y.2    Wang, J.3    Smith, G.J.D.4    Xu, K.M.5    Duan, L.6
  • 13
    • 0017151109 scopus 로고
    • Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N- Trifluoroacetyl -neuraminic acid (FANA): Mechanisms of action
    • Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N- trifluoroacetyl -neuraminic acid (FANA): mechanisms of action. J Gen Virol. 1976;33:159-63.
    • (1976) J Gen Virol , vol.33 , pp. 159-163
    • Palese, P.1    Compans, R.W.2
  • 14
    • 0020633096 scopus 로고
    • Structure of the catalytic and antigenic sites in influenza virus neuraminidase
    • Colman PM, Verghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983;303:41-4.
    • (1983) Nature , vol.303 , pp. 41-44
    • Colman, P.M.1    Verghese, J.N.2    Laver, W.G.3
  • 15
    • 0027287506 scopus 로고
    • Rational design of potent sialidase-based inhibitors of influenza virus replication
    • Von Itzstein M, Wu WY. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363:418-23.
    • (1993) Nature , vol.363 , pp. 418-423
    • Von Itzstein, M.1    Wu, W.Y.2
  • 16
    • 0027981472 scopus 로고
    • Inhibition of influenza virus replication in mice by GG167 is consistent with extracellular activity of viral neuraminidase (sialidase)
    • Ryan DM, Ticehurst J, Dempsey MH, Coates JA, Bethell RC. Inhibition of influenza virus replication in mice by GG167 is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother. 1994;38:2270-5.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 2270-2275
    • Ryan, D.M.1    Ticehurst, J.2    Dempsey, M.H.3    Coates, J.A.4    Bethell, R.C.5
  • 17
    • 0028049979 scopus 로고
    • Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium
    • Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res. 1994;25:123-31.
    • (1994) Antiviral Res , vol.25 , pp. 123-131
    • Hayden, F.G.1    Rollins, B.S.2    Madren, L.K.3
  • 18
    • 0034603350 scopus 로고    scopus 로고
    • Influenza virus neuraminidase inhibitors
    • Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355:827-35.
    • (2000) Lancet , vol.355 , pp. 827-835
    • Gubareva, L.V.1    Kaiser, L.2    Hayden, F.G.3
  • 20
  • 21
    • 0034720503 scopus 로고    scopus 로고
    • Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase inhibitor flu treatment investigator group
    • Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase inhibitor flu treatment investigator group. Lancet. 2000;355:1845-50.
    • (2000) Lancet , vol.355 , pp. 1845-1850
    • Nicholson, K.G.1    Aoki, F.Y.2    Osterhaus, A.D.3    Trottier, S.4    Carewicz, O.5    Mercier, C.H.6
  • 22
    • 20444436368 scopus 로고    scopus 로고
    • Human infection by avian influenza a H5N1
    • Yuen KY, Wong SSY. Human infection by avian influenza A H5N1. Hong Kong Med J. 2005;11:189-99.
    • (2005) Hong Kong Med J , vol.11 , pp. 189-199
    • Yuen, K.Y.1    Wong, S.S.Y.2
  • 23
    • 0033651178 scopus 로고    scopus 로고
    • The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses
    • Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000;48:101-15.
    • (2000) Antiviral Res , vol.48 , pp. 101-115
    • Leneva, I.A.1    Roberts, N.2    Govorkova, E.A.3    Goloubeva, O.G.4    Webster, R.G.5
  • 24
    • 0034801450 scopus 로고    scopus 로고
    • Comparison of efficacies of RWJ-270201, zanamivir and oseltamivir against H5N1, H9N2 and other avian influenza viruses
    • Govorkova E, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir and oseltamivir against H5N1, H9N2 and other avian influenza viruses. Antimicrob Agent Chemother. 2001;45:2723-32.
    • (2001) Antimicrob Agent Chemother , vol.45 , pp. 2723-2732
    • Govorkova, E.1    Leneva, I.A.2    Goloubeva, O.G.3    Bush, K.4    Webster, R.G.5
  • 26
    • 23244456655 scopus 로고    scopus 로고
    • Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice
    • Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis. 2005;192:665-72.
    • (2005) J Infect Dis , vol.192 , pp. 665-672
    • Yen, H.L.1    Monto, A.S.2    Webster, R.G.3    Govorkova, E.A.4
  • 27
    • 4444369826 scopus 로고    scopus 로고
    • Resistant influenza a viruses in children treated with oseltamivir: Descriptive study
    • Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-65.
    • (2004) Lancet , vol.364 , pp. 759-765
    • Kiso, M.1    Mitamura, K.2    Sakai-Tagawa, Y.3    Shiraishi, K.4    Kawakami, C.5    Kimura, K.6
  • 29
    • 0031978256 scopus 로고    scopus 로고
    • Emergence of drug resistance during an influenza epidemic: Insights from a mathematical model
    • Stilianakis NL, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis. 1998;177:863-73.
    • (1998) J Infect Dis , vol.177 , pp. 863-873
    • Stilianakis, N.L.1    Perelson, A.S.2    Hayden, F.G.3
  • 30
    • 0037397232 scopus 로고    scopus 로고
    • A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals
    • Ferguson NM, Mallett S, Jackson H, Roberts N, Ward P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother. 2003;51:977-90.
    • (2003) J Antimicrob Chemother , vol.51 , pp. 977-990
    • Ferguson, N.M.1    Mallett, S.2    Jackson, H.3    Roberts, N.4    Ward, P.5
  • 33
    • 0032741256 scopus 로고    scopus 로고
    • The economic impact of pandemic influenza in the United States: Priorities for intervention
    • Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis J. 1999;5:659-71.
    • (1999) Emerg Infect Dis J , vol.5 , pp. 659-671
    • Meltzer, M.I.1    Cox, N.J.2    Fukuda, K.3
  • 35
    • 0037636478 scopus 로고    scopus 로고
    • Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir
    • McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov M, Tashiro M, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47:2264-72.
    • (2003) Antimicrob Agents Chemother , vol.47 , pp. 2264-2272
    • McKimm-Breschkin, J.1    Trivedi, T.2    Hampson, A.3    Hay, A.4    Klimov, M.5    Tashiro, M.6
  • 36
    • 0036224388 scopus 로고    scopus 로고
    • Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo
    • Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel D, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002;54:79-88.
    • (2002) Antiviral Res , vol.54 , pp. 79-88
    • Carr, J.1    Ives, J.2    Kelly, L.3    Lambkin, R.4    Oxford, J.5    Mendel, D.6
  • 37
    • 0036294323 scopus 로고    scopus 로고
    • The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo
    • Ives J, Carr J, Mendel D, Tai CY, Lambkin R, Kelly L, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002;55:307-17.
    • (2002) Antiviral Res , vol.55 , pp. 307-317
    • Ives, J.1    Carr, J.2    Mendel, D.3    Tai, C.Y.4    Lambkin, R.5    Kelly, L.6
  • 38
    • 0034603350 scopus 로고    scopus 로고
    • Influenza virus neuraminidase inhibitors
    • Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355:827-35.
    • (2000) Lancet , vol.355 , pp. 827-835
    • Gubareva, L.V.1    Kaiser, L.2    Hayden, F.G.3
  • 39
    • 0033897803 scopus 로고    scopus 로고
    • Resistance of influenza viruses to neuraminidase inhibitors: A review
    • McKimm-Breschkin J. Resistance of influenza viruses to neuraminidase inhibitors: a review. Antiviral Res. 2000;47:1-17.
    • (2000) Antiviral Res , vol.47 , pp. 1-17
    • McKimm-Breschkin, J.1
  • 40
    • 0035190544 scopus 로고    scopus 로고
    • Comparison of the activities of zanamivir, oseltamivir and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
    • Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001;45:3403-8.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 3403-3408
    • Gubareva, L.V.1    Webster, R.G.2    Hayden, F.G.3
  • 42
    • 0036090557 scopus 로고    scopus 로고
    • Functional balance between haemagglutinin and neuraminidase in influenza virus infections
    • Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol. 2002;12:159-66.
    • (2002) Rev Med Virol , vol.12 , pp. 159-166
    • Wagner, R.1    Matrosovich, M.2    Klenk, H.D.3
  • 44
    • 0036228067 scopus 로고    scopus 로고
    • Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets
    • Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002;54:99-111.
    • (2002) Antiviral Res , vol.54 , pp. 99-111
    • Herlocher, M.L.1    Carr, J.2    Ives, J.3    Elias, S.4    Truscon, R.5    Roberts, N.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.